NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

• DOI: 10.6004/jnccn.2018.0072
• Publication Date: 2018-09-04T18:45:21Z
• Authors: Thomas W. Flaig; Philippe E. Spiess; Neeraj Agarwal; Rick Bangs; Stephen A. Boorjian; Mark K. Buyyounouski; Tracy M. Downs; Jason A. Efstathiou; Terence Friedlander; Richard E. Greenberg; Khurshid A. Guru; Noah Hahn; Harry W. Herr; Christopher Hoimes; Brant A. Inman; Masahito Jimbo; A. Karim Kader; Subodh M. Lele; Joshua J. Meeks; Jeff Michalski; Jeffrey S. Montgo...; Lance C. Pagliaro; Sumanta K. Pal; Anthony Patterson; Daniel P. Petrylak; Elizabeth R. Plimack; Kamal S. Pohar; Michael P. Porter; Mark A. Preston; Wade J. Sexton; Arlene O. Siefker...; Jonathan Tward; Geoffrey Wile; Alyse Johnson-Chilla; Mary A. Dwyer; Lisa A. Gurski
• Keywords: Patient Selection; Aftercare; Cystectomy; Medical Oncology; Neoadjuvant Therapy; United States; 3. Good health; 03 medical and health sciences; Administration, Intravesical; Treatment Outcome; 0302 clinical medicine; Urinary Bladder Neoplasms; Chemotherapy, Adjuvant; Lymphatic Metastasis; BCG Vaccine; Quality of Life; Humans; Radiotherapy, Adjuvant; Organ Sparing Treatments; Societies, Medical; Neoplasm Staging; Randomized Controlled Trials as Topic

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.